• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu

News

COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry

13 de April de 2022
J Natl Cancer Inst. 2022 Jul 11;114(7):979-987. doi: 10.1093/jnci/djac057.ABSTRACTBACKGROUND:…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2022-04-13 10:00:002022-04-13 10:00:00COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry

The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years

13 de April de 2022
Leukemia. 2022 Jun;36(6):1646-1653. doi: 10.1038/s41375-022-01563-8.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2022-04-13 10:00:002022-04-13 10:00:00The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years

Worldwide Network for Blood and Marrow Transplantation Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy

12 de April de 2022
Transplant Cell Ther. 2022 Aug;28(8):455-462. doi: 10.1016/j.jtct.2022.04.003.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2022-04-12 10:00:002022-04-12 10:00:00Worldwide Network for Blood and Marrow Transplantation Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy

Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study

10 de April de 2022
Eur Urol. 2022 Jul;82(1):22-30. doi: 10.1016/j.eururo.2022.02.023.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2022-04-10 10:00:002022-04-10 10:00:00Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study

Modification of BRCA1-associated breast cancer risk by HMMR overexpression

8 de April de 2022
Nat Commun. 2022 Apr 7;13(1):1895. doi: 10.1038/s41467-022-29335-z.ABSTRACTBreast…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2022-04-08 10:00:002022-04-08 10:00:00Modification of BRCA1-associated breast cancer risk by HMMR overexpression

Rethinking growth factors: the case of BMP9 during vessel maturation

30 de March de 2022
Vasc Biol. 2022 Feb 7;4(1):R1-R14. doi: 10.1530/VB-21-0019. eCollection…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2022-03-30 10:00:002022-03-30 10:00:00Rethinking growth factors: the case of BMP9 during vessel maturation

Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors

26 de March de 2022
J Immunother Cancer. 2022 Mar;10(3):e003255. doi: 10.1136/jitc-2021-003255.ABSTRACTBACKGROUND:…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2022-03-26 10:00:002022-03-26 10:00:00Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors

Metformin and Breast Cancer: Where Are We Now?

10 de March de 2022
Int J Mol Sci. 2022 Feb 28;23(5):2705. doi: 10.3390/ijms23052705.ABSTRACTBreast…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2022-03-10 11:00:002022-03-10 11:00:00Metformin and Breast Cancer: Where Are We Now?

Genomic and Epigenomic Landscape of Juvenile Myelomonocytic Leukemia

10 de March de 2022
Cancers (Basel). 2022 Mar 4;14(5):1335. doi: 10.3390/cancers14051335.ABSTRACTJuvenile…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2022-03-10 11:00:002022-03-10 11:00:00Genomic and Epigenomic Landscape of Juvenile Myelomonocytic Leukemia

Depletion of CCN1/CYR61 reduces triple-negative/basal-like breast cancer aggressiveness

9 de March de 2022
Am J Cancer Res. 2022 Feb 15;12(2):839-851. eCollection 2022.ABSTRACTTriple-negative/basal-like…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2022-03-09 11:00:002022-03-09 11:00:00Depletion of CCN1/CYR61 reduces triple-negative/basal-like breast cancer aggressiveness

Promalignant effects of antiangiogenics in the tumor microenvironment

6 de March de 2022
Semin Cancer Biol. 2022 Nov;86(Pt 3):199-206. doi: 10.1016/j.semcancer.2022.03.003.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2022-03-06 11:00:002022-03-06 11:00:00Promalignant effects of antiangiogenics in the tumor microenvironment

Facile Synthesis of Unsupported Pd Aerogel for High Performance Formic Acid Microfluidic Fuel Cell

25 de February de 2022
Materials (Basel). 2022 Feb 15;15(4):1422. doi: 10.3390/ma15041422.ABSTRACTIn…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2022-02-25 11:00:002022-02-25 11:00:00Facile Synthesis of Unsupported Pd Aerogel for High Performance Formic Acid Microfluidic Fuel Cell
Page 34 of 88«‹3233343536›»

Filter by categories

  • Alemany’s & Piulats’s lab (135)
  • Antolin's lab (36)
  • Aytes's Lab (25)
  • Belver's Lab (25)
  • Casanovas's Lab (77)
  • Martínez-Balibrea's Lab (43)
  • Menendez's Lab (121)
  • Molleví's Lab (35)
  • Pujana's Lab (112)
  • Sin categoría (12)
  • Sureda's & Farre's Lab (319)
  • Viñals's lab (114)

Twitter

Tweets by ProcureICO
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}